News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bay Area's Ardelyx Inc. Lowers IPO Target Slightly, Now Hopes To Raise Up To $62 Million


6/11/2014 7:10:23 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Biotech company Ardelyx updated its IPO plans on Monday, saying it now hopes to raise up to $62 million. That is down from a top target of $69 million that the Fremont company disclosed when it first made its plans public three weeks ago. Ardelyx, led by CEO Michael Raab, works on small molecule treatments for kidney and gastrointestinal disease.

Help employers find you! Check out all the jobs and post your resume.

Read at Silicon Valley


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES